- BMS-1
-
- $34.00
-
2026-07-14
- CAS:1675201-83-8
- Purity: 99.56%
- Supply Ability: 10g
|
| | 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Basic information |
| Product Name: | 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- | | Synonyms: | T3655;(2S)-1-{2,6-Dimethoxy-4-[(2-methyl-3-biphenylyl)methoxy]benzyl}-2-piperidinecarboxylic acid;2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)-;PD1-PDL1 inhibitor 1;PD-1PD-L1 inhibitor;(2S)-1-[[2,6-Dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-2-piperidinecarboxylic acid;avelumab/PD-L1;PD1-PDL1 inhibitor 1 (PD1-PDL1-IN1) | | CAS: | 1675201-83-8 | | MF: | C29H33NO5 | | MW: | 475.58 | | EINECS: | | | Product Categories: | | | Mol File: | 1675201-83-8.mol | ![2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Structure](CAS/20180702/GIF/1675201-83-8.gif) |
| | 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Chemical Properties |
| Boiling point | 630.2±55.0 °C(Predicted) | | density | 1.182±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to 20 mg/ml) | | form | solid | | pka | 2.34±0.20(Predicted) | | color | White | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| | 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Usage And Synthesis |
| Description | PD-1/PD-L1 Inhibitor 1 (1675201-83-8) inhibits (IC50 = <100nM) the formation of the PD-1/PD-L1 complex via binding to PD-L1 and inducing dimerization.1 | | Uses | BMS-1 is a PD-L1 inhibitor which is used in combination with LIF inhibitors for the treatment of cancers. | | in vitro | pd-1/pd-l1 inhibitor 1 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (pd-1) with its ligand protein (pd-l1). pd-1/pd-l1 inhibitor 1 was also found to act as an immunomodulator. in preclinical studies, pd-1/pd-l1 inhibitor 1 was able to block pd-1/pd-ll interactions with an ic50 value between 6 and 100 nm, which was measured by a homogenous time-resolved fluorescence (htrf) binding assay. thus, pd-1/pd-l1 inhibitor 1 might potentially be used for the treatment of cancer as well as infectious diseases, such as hepatitis c [1]. | | in vivo | BMS-1 (500 μg/mL; 100 μL; i.p.) significantly increases the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group[3].
| Animal Model: | BALB/c mice with EMT6 cells[3] | | Dosage: | 500 μg/mL; 100 μL | | Administration: | I.p. | | Result: | Increased the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group.
mVEGF165b combined with MUC1 results significant retardation of the tumor growth. |
| | IC 50 | 0.006-0.10 μm | | References | [1] OLIVER KAYSER Albrecht F K K Noël Masihi. Natural products and synthetic compounds as immunomodulators.[J]. Expert Review of Anti-infective Therapy, 2003: 319-335. DOI:10.1586/14787210.1.2.319 |
| | 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Preparation Products And Raw materials |
|